vTv Therapeutics (VTVT) IPO Opens 7% Lower
Get Alerts VTVT Hot Sheet
Join SI Premium – FREE
Today's IPO for vTv Therapeutics (NASDAQ: VTVT) opened for trading at $14 after pricing 7,812,500 shares of its Class A common stock at a price to the public of $15 per share, the low end of the expected $15-$17 range.
Piper Jaffray & Co. and Stifel are acting as joint book-running managers for the offering. In addition, Canaccord Genuity Inc. and Janney Montgomery Scott LLC are acting as co-managers for the offering.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neo-Concept International Group Holdings (NCI) Prices 2.32M Share IPO at $4/sh
- Viking Holdings (VIK) Announces 44M Share IPO at $21-$25/sh
- Five9, Inc (FIVN) PT Lowered to $75 at Canaccord Genuity
Create E-mail Alert Related Categories
IPOsRelated Entities
Piper Jaffray, Janney Montgomery Scott, Canaccord Genuity, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!